EP 0998300 A1 20000510 - METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS
Title (en)
METHODS AND COMPOSITIONS FOR MODULATING RESPONSIVENESS TO CORTICOSTEROIDS
Title (de)
ZUSAMMENSETZUNGEN ZUR MODULATION DER EMPFÄNGLICHKEIT FÜR CORTICOSTEROIDEN
Title (fr)
PROCEDES ET COMPOSITIONS PERMETTANT DE MODULER LA SENSIBILITE AUX CORTICOSTEROIDES
Publication
Application
Priority
- US 9804916 W 19980312
- US 82069297 A 19970318
- US 1634698 A 19980130
Abstract (en)
[origin: WO9841232A2] Method for modulating responsiveness to corticosteroids in a subjet are provided. In the method of the invention, an agent which antagonizes a target that regulates production of IFN- gamma in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an IL-18 antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In yet another embodiment, the agent is an NK cell antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. In yet another preferred embodiment, the agent is an anti-asialo-GM1 antibody or an NK1.1 antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a target that regulates production of IFN- gamma in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.
IPC 1-7
IPC 8 full level
A61K 31/40 (2006.01); A61K 45/06 (2006.01); A61K 31/505 (2006.01); A61K 38/20 (2006.01); A61K 38/46 (2006.01); A61K 39/395 (2006.01); A61P 3/10 (2006.01); A61P 9/02 (2006.01); A61P 11/06 (2006.01); A61P 37/06 (2006.01); A61P 43/00 (2006.01); C07K 16/24 (2006.01)
IPC 8 main group level
A61P 29/00 (2006.01)
CPC (source: EP KR)
A61K 31/4015 (2013.01 - EP); A61K 31/573 (2013.01 - EP); A61K 38/1793 (2013.01 - EP); A61K 39/00 (2013.01 - KR); A61K 45/06 (2013.01 - EP); A61P 3/10 (2018.01 - EP); A61P 9/02 (2018.01 - EP); A61P 11/06 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 37/06 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07K 16/244 (2013.01 - EP)
C-Set (source: EP)
Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
DOCDB simple family (publication)
WO 9841232 A2 19980924; WO 9841232 A3 20001005; AU 6760498 A 19981012; AU 734756 B2 20010621; BG 103808 A 20000731; BR 9810409 A 20000822; CA 2282845 A1 19980924; CN 1269722 A 20001011; DE 998300 T1 20010301; EP 0998300 A1 20000510; ES 2146192 T1 20000801; HU P0104439 A2 20020429; HU P0104439 A3 20020828; ID 22975 A 19991223; IL 131815 A0 20010319; JP 2002504091 A 20020205; KR 20000076420 A 20001226; NO 994506 D0 19990917; NO 994506 L 19991117; NZ 337769 A 20020927; PL 336464 A1 20000619; SI 20110 A 20000630; SK 122199 A3 20001211; TR 199902615 T2 20000321
DOCDB simple family (application)
US 9804916 W 19980312; AU 6760498 A 19980312; BG 10380899 A 19991013; BR 9810409 A 19980312; CA 2282845 A 19980312; CN 98805124 A 19980312; DE 98912929 T 19980312; EP 98912929 A 19980312; ES 98912929 T 19980312; HU P0104439 A 19980312; ID 991185 A 19980312; IL 13181598 A 19980312; JP 54063398 A 19980312; KR 19997008524 A 19990918; NO 994506 A 19990917; NZ 33776998 A 19980312; PL 33646498 A 19980312; SI 9820032 A 19980312; SK 122199 A 19980312; TR 9902615 T 19980312